Athenex, Inc. to Report First Quarter 2020 Earnings Results on May 7, 2020
April 23 2020 - 8:00AM
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of
novel therapies for the treatment of cancer and related conditions,
today announced that it will release first quarter 2020 financial
results on Thursday, May 7, 2020, before the market opens, and host
a conference call and live audio webcast 8:00am Eastern Time to
discuss the financial results and provide a business update.
To participate in the call, dial 800-479-1004 (domestic) or
929-477-0324 (international) fifteen minutes before the conference
call begins and reference the conference passcode 7976288.
The live conference call and replay can also be accessed via audio
webcast at the Investor Relations section of the Company’s website,
located at http://ir.athenex.com/.
About Athenex, Inc. Founded in 2003,
Athenex, Inc. is a global clinical stage biopharmaceutical company
dedicated to becoming a leader in the discovery, development and
commercialization of next generation drugs for the treatment of
cancer. Athenex is organized around three platforms, including an
Oncology Innovation Platform, a Commercial Platform and a Global
Supply Chain Platform. The Company’s current clinical pipeline is
derived from four different platform technologies: (1) Orascovery,
based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3)
T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine
deprivation therapy. Athenex’s employees worldwide are dedicated to
improving the lives of cancer patients by creating more active and
tolerable treatments. Athenex has offices in Buffalo and
Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago,
Illinois; Hong Kong; Taipei, Taiwan; multiple locations in
Chongqing, China; Manchester, UK; Guatemala City, Guatemala and
Buenos Aires, Argentina. For more information, please visit
www.athenex.com.
CONTACTSInvestor Relations:Tim McCarthyManaging
Director, LifeSci Advisors, LLCDirect: 212-915-2564
Athenex, Inc.:Randoll SzeChief Financial OfficerEmail:
RandollSze@athenex.com
Jacqueline LiCorporate Development and Investor RelationsEmail:
JacquelineLi@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Apr 2023 to Apr 2024